
OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help biotech and pharmaceutical companies with drug development, as announced on Tuesday. The acquisition brings Orchestra Bio's team and technology together with Rosalind, OpenAI's AI models and tools for life sciences research. According to OpenAI's announcement, the acquisition brings Orchestra Bio's team and technology together with Rosalind, OpenAI's AI models and tools for life sciences research. The company stated its goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner. As per OpenAI, this acquisition represents a significant step toward realizing AI's potential in life sciences research, moving the company's life sciences work beyond scientific reasoning and into program execution.
Developing a new medicine takes roughly 10 to 15 years on average, from target discovery to regulatory approval in the United States, as cited by OpenAI. The company highlighted the complexity of scientific research and coordination required across internal teams and external partners. OpenAI noted they are now at an inflection point where AI can help take on these specialized tasks and complex workflows in the pharmaceutical sector. Beyond the science, teams must orchestrate programs across internal departments and external partners, often relying on disconnected systems. Orchestra Bio's platform addresses these coordination challenges by providing a unified approach to drug development management, where scientists and AI agents work together to monitor drug development programmes, track studies and identify potential delays.
OpenAI's Rosalind platform includes GPT-Rosalind, which helps scientists reason through questions in biology and chemistry, and Rosalind Workbench, which connects AI capabilities with scientific tools and data to help researchers analyze results and plan experiments. Orchestra Bio provides a platform where scientists and AI agents work together to monitor drug development programmes, track studies and identify potential delays. The platform assigns AI agents to monitor studies and campaigns while qualified people retain accountability for quality and release decisions in regulated settings. In regulated settings, Orchestra's agents identify which activities and timelines are affected when issues like failed batches occur, gather relevant information, and compare possible responses. This division of labor between AI agents and qualified personnel is significant in regulated settings where accountability for quality and release decisions rests with qualified people rather than software.
OpenAI highlighted collaboration with companies at the forefront of drug discovery and development as critical to realizing AI's potential in the sector. The company referenced its partnership with Novo Nordisk, stating it aims to translate the company's scale and scientific expertise into faster R&D and commercial execution while maintaining strong governance. Additionally, OpenAI noted AI is helping teams at Moderna translate insights from complex data into experimental workflows, with potential to accelerate R&D. The collaboration aims to make more discoveries possible and help new medicines reach patients sooner through AI-powered operations. Much of the industry's AI spending so far has focused on the earliest stages of development, as noted by Megha Sinha, founder and CEO of Kolter AI.
The acquisition comes as rival AI company Anthropic also pushes into life sciences, having acquired AI biotech startup Coefficient Bio for roughly $400 million in April, as reported by The Information. Anthropic launched Claude Science in June, an AI-powered research platform that connects scientific databases, analysis tools and specialized agents. In September, the company announced a new biological research lab and said Claude had helped discover a previously unknown enzyme system with similarities to CRISPR. OpenAI introduced its specialized GPT-Rosalind model in April to help researchers tackle complex problems in biology, chemistry and drug discovery, positioning the company to compete effectively in the expanding AI-powered drug development market.